193 related articles for article (PubMed ID: 21965765)
1. Patterns of failures in endometrial cancer: clinicopathological variables predictive of the risk of local, distant and retroperitoneal failure.
Gadducci A; Cosio S; Fabrini MG; Fanucchi A; Barsotti C; Cristofani R; Greco C; Genazzani AR
Anticancer Res; 2011 Oct; 31(10):3483-8. PubMed ID: 21965765
[TBL] [Abstract][Full Text] [Related]
2. Lymph-vascular space involvement and outer one-third myometrial invasion are strong predictors of distant haematogeneous failures in patients with stage I-II endometrioid-type endometrial cancer.
Gadducci A; Cavazzana A; Cosio S; DI Cristofano C; Tana R; Fanucchi A; Teti G; Cristofani R; Genazzani AR
Anticancer Res; 2009 May; 29(5):1715-20. PubMed ID: 19443392
[TBL] [Abstract][Full Text] [Related]
3. Analysis of FIGO Stage IIIc endometrial cancer patients.
McMeekin DS; Lashbrook D; Gold M; Johnson G; Walker JL; Mannel R
Gynecol Oncol; 2001 May; 81(2):273-8. PubMed ID: 11330962
[TBL] [Abstract][Full Text] [Related]
4. Lymph-vascular space invasion and number of positive para-aortic node groups predict survival in node-positive patients with endometrial cancer.
Watari H; Todo Y; Takeda M; Ebina Y; Yamamoto R; Sakuragi N
Gynecol Oncol; 2005 Mar; 96(3):651-7. PubMed ID: 15721407
[TBL] [Abstract][Full Text] [Related]
5. Lymphvascular space involvement: an independent prognostic factor in endometrial cancer.
Briët JM; Hollema H; Reesink N; Aalders JG; Mourits MJ; ten Hoor KA; Pras E; Boezen HM; van der Zee AG; Nijman HW
Gynecol Oncol; 2005 Mar; 96(3):799-804. PubMed ID: 15721428
[TBL] [Abstract][Full Text] [Related]
6. An intensive follow-up does not change survival of patients with clinical stage I endometrial cancer.
Gadducci A; Cosio S; Fanucchi A; Cristofani R; Genazzani AR
Anticancer Res; 2000; 20(3B):1977-84. PubMed ID: 10928137
[TBL] [Abstract][Full Text] [Related]
7. Pelvic lymph node count is an important prognostic variable for FIGO stage I and II endometrial carcinoma with high-risk histology.
Lutman CV; Havrilesky LJ; Cragun JM; Secord AA; Calingaert B; Berchuck A; Clarke-Pearson DL; Soper JT
Gynecol Oncol; 2006 Jul; 102(1):92-7. PubMed ID: 16406063
[TBL] [Abstract][Full Text] [Related]
8. Predictors of lymphatic failure in endometrial cancer.
Mariani A; Webb MJ; Keeney GL; Aletti G; Podratz KC
Gynecol Oncol; 2002 Mar; 84(3):437-42. PubMed ID: 11855884
[TBL] [Abstract][Full Text] [Related]
9. [Survival, prognostic factors and modern tendencies in adjuvant treatment of diagnosed endometrial cancer patients with or without lymph node dissection].
Ivanov I
Akush Ginekol (Sofiia); 2009; 48 Suppl 1():3-11. PubMed ID: 20387272
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant chemotherapy as treatment of high-risk stage I and II endometrial cancer.
Aoki Y; Watanabe M; Amikura T; Obata H; Sekine M; Yahata T; Fujita K; Tanaka K
Gynecol Oncol; 2004 Aug; 94(2):333-9. PubMed ID: 15297170
[TBL] [Abstract][Full Text] [Related]
11. [Pelvic lymphadenectomy as an alternative to adjuvant radiotherapy in early stage endometrial cancer at high risk of recurrent lymphatic metastases (stage I)].
Amato NA; Partipilo V; Mele F; Boscia F; De Marzo P
Minerva Ginecol; 2009 Feb; 61(1):1-12. PubMed ID: 19204656
[TBL] [Abstract][Full Text] [Related]
12. High-risk endometrial cancer subgroups: candidates for target-based adjuvant therapy.
Mariani A; Dowdy SC; Keeney GL; Long HJ; Lesnick TG; Podratz KC
Gynecol Oncol; 2004 Oct; 95(1):120-6. PubMed ID: 15385120
[TBL] [Abstract][Full Text] [Related]
13. Hematogenous dissemination in corpus cancer.
Mariani A; Webb MJ; Keeney GL; Calori G; Podratz KC
Gynecol Oncol; 2001 Feb; 80(2):233-8. PubMed ID: 11161865
[TBL] [Abstract][Full Text] [Related]
14. Retrospective analysis of prognostic variables and clinical outcomes in surgically staged intermediate risk endometrial carcinoma.
Zhang GY; Wu LY; Li B; Huang MN; Zhang R; Li XG
Eur J Obstet Gynecol Reprod Biol; 2013 Jul; 169(2):309-16. PubMed ID: 23540792
[TBL] [Abstract][Full Text] [Related]
15. Lymphovascular space invasion is highly associated with lymph node metastasis and recurrence in endometrial cancer.
Hahn HS; Lee IH; Kim TJ; Lee KH; Shim JU; Kim JW; Lim KT
Aust N Z J Obstet Gynaecol; 2013 Jun; 53(3):293-7. PubMed ID: 23600915
[TBL] [Abstract][Full Text] [Related]
16. A comparison of stages IB1 and IB2 cervical cancers treated with radical hysterectomy. Is size the real difference?
Rutledge TL; Kamelle SA; Tillmanns TD; Gould NS; Wright JD; Cohn DE; Herzog TJ; Rader JS; Gold MA; Johnson GA; Walker JL; Mannel RS; McMeekin DS
Gynecol Oncol; 2004 Oct; 95(1):70-6. PubMed ID: 15385112
[TBL] [Abstract][Full Text] [Related]
17. Stage III endometrial cancer: analysis of prognostic factors and failure patterns after adjuvant chemotherapy.
Aoki Y; Kase H; Watanabe M; Sato T; Kurata H; Tanaka K
Gynecol Oncol; 2001 Oct; 83(1):1-5. PubMed ID: 11585406
[TBL] [Abstract][Full Text] [Related]
18. Lymphovascular space invasion does not predict vaginal relapses in stage I endometrioid adenocarcinoma of the endometrium.
Desrosiers L; Fadare O; Xiao ZF; Dresser K; Wang SA
Ann Diagn Pathol; 2008 Apr; 12(2):112-7. PubMed ID: 18325471
[TBL] [Abstract][Full Text] [Related]
19. Endometrioid uterine cancer: histopathological risk factors of local and distant recurrence.
Fujimoto T; Nanjyo H; Fukuda J; Nakamura A; Mizunuma H; Yaegashi N; Sugiyama T; Kurachi H; Sato A; Tanaka T
Gynecol Oncol; 2009 Feb; 112(2):342-7. PubMed ID: 19062082
[TBL] [Abstract][Full Text] [Related]
20. Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer--A pooled analysis of PORTEC 1 and 2 trials.
Bosse T; Peters EE; Creutzberg CL; Jürgenliemk-Schulz IM; Jobsen JJ; Mens JW; Lutgens LC; van der Steen-Banasik EM; Smit VT; Nout RA
Eur J Cancer; 2015 Sep; 51(13):1742-50. PubMed ID: 26049688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
